Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Aiforia, Webcast, Q2'26

By Inderes8/28/2026, 7:00 AM
Aiforia Technologies

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jukka Tapaninen
00:03 - 33:01

Good morning and welcome to Aiforia Technologies Plc's first-half earnings announcement event. Today, we have two presenters: myself and our CFO, Antti Ojala. We will start with the business highlights of what happened in the past six months. And after that. We will then move on to the financial results of the event. And after that, of course, there is room for questions and answers. It has been an interesting first half, and I would say we have been moving forward and gaining new customers. As you may know, we already have a contract with the Assistance Publique-Hôpitaux De Paris. The Paris hospital region is the biggest one in Europe. It has 38 hospitals, and they are already successfully using our prostate models in production, including in the first half of the year. We secured an additional five hospitals from that group. This is a significant achievement on that front. France as a market is also interesting, as the government has a program in place to fund the first two years of use for AI models. And Aiforia Technologies Plc is the only AI solution for diagnostics that has been accepted for that program. That is why we have been fairly successful in the French market and expect that it will be a major market in the coming months and years. Another significant deal we made was in Spain. We already have a presence in the Castilla-León region in Spain, which is quite significant. And now we have secured an additional healthcare region in the country. That is moving forward nicely. And of course, there have been some smaller deals happening. I think these are the major clinical achievements from the first half. Then let's look at the partner network, because this is an ecosystem play. We provide an AI solution to support diagnostic decision-making in pathology. We provide AI solutions to support diagnostic decision-making in pathology, such as analyzing cancer samples and supporting diagnostic decisions. However, there are plenty of other components, such as software and hardware vendors, that we need to partner with. We are already collaborating with all the major scanner manufacturers. In addition to scanner manufacturers, we also collaborate with image management vendors like Proscia. Proscia is one of those new partnerships. We have established. And it is a logical one because we had already established the relationship last year. When Siemens chose us to be part of their program, Proscia was already there. Proscia is providing the image management part, and we are providing the AI-assisted diagnostic part of that offering. Proscia was one of the many meaningful partnerships in the first half. And of course, we did the IPO, as you remember, back in 2021. When we completed it. We promised that. Okay. We started building a portfolio for the clinical side and focused on getting the first referenceable customers in the clinical market. I will return to the customer side in the next slide, but also discuss the product side. We have been moving forward nicely. I believe we have the best and most competitive portfolio in this market. We currently have 12 CE-IVD solutions. In the first half of the year, we added an additional two models to our portfolio. And one of our targets was to have a portfolio of AI tools that covers more or less 80% of the typical clinical workflow. And that target was by the end of the decade. We are on a good trajectory regarding that. We are clearly over 50% of the workflow coverage. From a solution perspective, we are moving forward nicely. We are also adapting new technologies, such as foundation models, and upgrading our offerings to meet today's standards. But that is moving forward really nicely. And of course, as we are a growth company and investing heavily in R&D, we are also investing heavily in building the market. We need funding. We have completed two major activities in the first half of the year. First of all, we negotiated the loan arrangement with the EIB. Antti will cover that a little bit more in detail later on in this presentation. And then we did this directed share issue in June. All in all, our financial position is getting much better by doing these two activities. It also indicates that the market still trusts the industry and us to perform well in this space. All right. I would say that this is probably the most meaningful slide in my presentation. Because this is a new industry, some competitors have solutions for one particular problem, such as prostate or breast cancer. But we have a wide portfolio. And very few companies have all the regulatory parts sorted out. Having the CE-IVD mark and all necessary security-related certifications in place is essential to successfully sell into this market. But the last point is that you have been successfully selling and delivering, and the customers are actively using the solution. You can see on the right-hand side that barometer or volume button. We have listed the customers we have because the complexity here is that, while we have closed really nice deals, we need to consider who has started to use the solution. Not all are in full production. None of them are actually in full production, with the exception of the Mayo Clinic. We have been very successful. Four years ago, we already made a deal. We have delivered the breast cancer suite, and it has been in production for multiple years. But there is a lot of upsell opportunity at the Mayo Clinic as well. The same applies to a couple of others. I would mention the NHS, which we signed three years ago. Done deal. It is now implemented. We have received the funds from the deal and the customer is starting to use it now. But it is not in production yet, which is interesting. But there are multiple reasons why the customers are not starting to use it immediately. Our deliveries are fairly fast. We can deliver our software solution in more or less a month. But then there is the complexity of all the other solutions. Some customers are upgrading their systems and we need to wait until that is done. Some customers have not yet invested in enough scanners to have a sufficient volume of digital images to ramp up usage, but all are moving forward on that track because scanners and image management systems are quite expensive investments. But the gains are coming from AI and AI-assisted diagnostics. So in a way, we are in a good position, but unfortunately, there is a certain time lag between closing the contract and the customer starting to use it. So. And on that barometer, the green ones are the ones who are actually in production. The yellow ones are those that have been delivered, and production routine use is just starting. And then you have a list of customers for which a contract has been signed and they will start using it. However, there is a slight delay when implementation occurs. But all in all, we have roughly 20 clinical customers today. And when everything is up and running at the right volume. So there are already significant revenues coming from that side. However, there is a time lag in terms of implementation regarding when it goes live. But these are all happening for sure. But the timing is the key, and the positive thing is that, like in Paris, we already have multiple hospitals, and we have a few of them in production already. So when we now sign up with those additional five hospitals, it means that the core software and all the surrounding systems have been implemented and all integrations are done when they start using it. It actually happens much faster than with a greenfield customer. If we work with a customer that first transitions to digital pathology, they then progress to AI-assisted diagnostics. So then there is a time lag. When they transform the organization, get all the tools in place, and then they start using it. But when we sell to these customers who already have something in production and we upsell, it happens really fast. There are different types of customers in play. And that links a little bit back to the previous slide. We currently have at least two different types of revenue generation models in place. We have a right-to-access and a right-to-use model. The difference is that if we implement the software on the customer's cloud or on-premise, then it is a right-to-use model. When the software is implemented on the Aiforia Technologies Plc hosted cloud. So then the revenue recognition will happen in a different way. We used to have a slightly higher proportion of these "right to use" customers. It will show a little bit in our numbers as well that you could recognize when the usage started, the whole block, and when it is in the Aiforia Technologies Plc environment. So then the recognition will happen over the years. It is a software-as-a-service type of model that we are moving toward increasingly. But in the long run, I think that is really sustainable and a good model to move forward. However, there are different types of models in place, plus two types of customers. So, is it a totally new greenfield customer, or is it already an existing customer? And I can give another example, Paris was one, but we have this big deal in Lombardia. We have implemented the software, and we were able to recognize some revenue last year. However, there are 32 hospitals and there is a specific rollout plan. They are implementing this hospital by hospital as they begin using the software. It is a three-year plan so that as they ramp up production in that organization, it will eventually become a very good, profitable, and large customer for us. However, it happens step by step. When we close a deal with a customer who has a million slides, it is important to understand the process. So then somebody calculates that immediately it is revenue like that. It will be, but it needs to go through those steps step by step. But we can, of course, answer some questions on this topic in the Q&A part. The other positive thing is that the market is there. The demand for these solutions has not changed. So that. Okay, the market is growing. There are a couple of drivers for that. Cancer cases are unfortunately increasing. And the demand is there. On the other hand, the number of pathologists is remaining stagnant or declining. There was a statistic from the US, but it applies all over the world quite well. 40% of pathologists are over 60 years old. Meaning that on the other side, the volume is picking up. You need to do more, and at the same time, in the coming years. So the. Most of these, or at least some of these professionals, are approaching retirement. And the number of people who can actually handle that manually is disappearing. It's disappearing. I mentioned this example last time, but in the Lombardia case, they have 409 pathologists; 100 are retiring in the next two years and only nine new ones are joining, so they will lose roughly 20% to 25% of their workforce. And that is the reason that they have to move toward modernization and start using the latest technology. So the demand is there, the need is there. That is for sure. And of course, the expectations for diagnostics and clinical diagnosis are becoming increasingly higher. It is more complex. You test multiple things. You want to give the patient better and more precise treatment. In a way, the complexity is growing. The capabilities to analyze those samples with the human eye do not provide the precise results required for the next steps in treatment or medication decisions. All of these drivers are moving in the direction that the market is there, and the market is growing. On that topic. We have modified the slide on the workflow because we have always talked about taking the physical samples, preparing the slides, performing the staining, and doing the scanning. But if you look at the digital pathology market and AI-assisted diagnostics market, that is a big trend in this area. There is a lot of interest in the ecosystem. There has been a lot of partnering happening already. Some really significant acquisitions have been happening. But the thing is that, when you sell scanners or image management, you cannot sell it without having an AI story on top of that, because AI is what brings the value to this whole play. And that is the position where Aiforia Technologies Plc is in our market. It is going to grow nicely. Plus 17% on an annual basis going forward. Yes. It is a new market. We need to enter the market. We have a fantastic offering. We have the references. We are in a good position on that. But we are also thinking that. We also want to expand our footprint within the customer base, making Aiforia Technologies Plc more strategic in that sense. If we talk about image management and workflow. We work with all the major companies on that side and have integrations. But every single one of these 20 plus customers on the clinical side, when they receive AI-driven results, they view the images and the reports through the Aiforia Technologies Plc viewer. Basically, we are already there on the image management side. What we are missing is a little bit of workflow management and a little bit on storing the images, the PACS side of that market. But we are already heavily involved on the image management side. As I mentioned, we are focusing on developing an AI-native diagnostic tool for these types of samples. And that includes some of the functionality from our image management side. Meaning that our addressable market is growing in that direction and also toward the other side. We already have a predictive model developed with the Mayo Clinic for colorectal cancer. So that you can predict the patient outcome and link the treatment to that information. But we also this week, some of you may have noticed, we announced a partnership with a Swedish company that is doing prognostic models as well. That is the next step. When AI has completed the diagnosis for the H&E and IHC slides, users can now order a report through the Aiforia Technologies Plc viewer. Just one click provides a risk assessment for breast cancer cases. That is additional business. This is a market that is only available when the AI is in place. But it is definitely moving in that direction. The value for AI on that side is steadily increasing. My point here is that we are in an interesting market in a key position on that. Plus, we are expanding our addressable market by having a more complete solution to offer, effectively positioning ourselves to be more strategic for our end customers. That is the big picture. On the product side, this is a really competitive offering. What we have. Typically, when we go to a head-to-head comparison, we win. That is really good news. Our idea when we started to build this was that we are not just focusing on one algorithm. We are actually providing a platform and enough solutions so that you can cover the majority of the workflow, providing a unified user experience and solid results for the users, but also addressing tactical things as well. We recognize the financial results and are explaining the reasons why revenue recognition has been slightly delayed, but we have implemented changes on a tactical level. We will actually have a new Chief Commercial Officer. He starts next week. We have been recruiting more direct salespeople. We are shifting the company to focus on the scaling-up phase. As we focus on scaling up. We have these elements to ensure that our direct sales team is truly strong. I expect that will drive most of the deals we will secure going forward. At the same time, we invested in building up the channel. We have a reselling channel network globally consisting of over 30 companies. But I would say that a handful are really relevant. But we set up an organization so that we can support and train the partners and scale up the business through the channel. That was one of the concrete actions we took, and we have certain markets like the Nordics, France, the US, and Italy where we have good direct presence. We have direct salespeople in place in certain markets, while other markets need to be addressed through the partner network. We want to scale this up and bring our management of it to a more professional level. The other concrete thing that we did. We have also established a separate team for customer success management. Now that we have enough customers, including over 20 clinical customers, it is really important that they actually start using our solutions in real-life production. We want, of course, to find new opportunities to expand our footprint, and to determine how we can add more AI models to our portfolio and so on. We are focused on being with the customer and identifying where the bottlenecks are and what issues they face. We address those issues, focus on upsell, and make sure that the customers are happy and using our solution. However, those two concrete organizational changes were key. Plus, of course, in sales and marketing overall. We have been looking at new ways to find potential customers, specifically those that fit our ideal customer profile. Then we set up all the basic things to qualify those leads and see where we should actually invest. Where do we have a good opportunity to close and win? We prioritize our investment, but I do not want to go into too much tactical detail here; rather, I want to show that we have been continuously following up to determine what works and what does not. And then we try to improve the activities that we have on the go-to-market side. Then, regarding our mid-term business targets. Nothing has changed since the last time. We are aiming for financial independence by the end of 2027. We can cover this in the next part and during the questions as well. But it means that we of course expect the sales to grow. We need to control our costs and ensure that our financing remains in good shape so that we can continue. However, we see this market picking up. We are ready to invest. We are ready to capture the opportunities. And I mentioned this portfolio 80%. We are well on track on that side. The offering is good. We will add a few more models, but we already have enough to sell. Having a good, solid quality product is no longer a problem. We have the portfolio, and now it is time to monetize that. I would say we aim to achieve 50 key accounts. We have 20, and we aim to reach 50 or even more. So 50 is the target number. But it just tells you that we want to grow a bigger organization. We have significant volumes, and each of these 50 key accounts should have more than half a million in annual revenue potential. It does not happen immediately, but it has to be a sizable organization that we can grow to that level. And then it's a good, profitable business for us, and it's a good business and a valuable acquisition for the customer as well. And then, of course, the technology. So, I have told you about the markets, how we expand, and what type of ideas we have there. We are well on track on that side. So the offering is good. So we will add a few more models, but we already have enough to sell. Having a solid quality product is no longer a problem. So we have the portfolio and now it is time to monetize that. I would say then to achieve 50 key accounts. But that is it from my side. I will be back to answer your questions, but now I will hand it over to Antti to continue. Okay. Thank you, Jukka, and good morning, everybody. Also on my behalf, as already mentioned, my name is Antti Ojala. I am the new CFO of Aiforia Technologies Plc. It is my pleasure and honor to be here giving a presentation. This is my first time participating in an earnings call. Before starting, I just want to remind you that the numbers in the parentheses in the financial part are from the reference period, H1 2025. The group revenue was €753,000 last year. During the same period, the revenue was close to €1.4 million. From a geographical perspective, 43% of the revenue came from Europe and other regions. One third of the revenue came from North America and 24% came from Finland. As a Finnish company, we are happy that we have good Finnish customers, and it is also important that we can show good presence in the domestic market. The investments during the period were €2.9 million. Last year, investments for the same period were €3.7 million. The investments were mainly capitalized R&D expenses. EBITDA for the reported period was -€4.7 million. In the same period, the EBITDA was -€3 million. The EBITDA was impacted, obviously, by a decrease in revenue, but there was also one large one-off non-cash item of €1.1 million that was related to a decision to extend the subscription period of employee stock option plans. The EBIT was further impacted by an increase in depreciation and amortization in accordance with the plan. The number of employees stayed almost at the same level as last year, and our average headcount was 68 employees. During the first half, the cash at banks was €9.9 million at the end of June 2025. At the end of June, the cash at banks was close to €12 million. The order book was €3.5 million. At the end of June 2026. The order book stayed on the same level as it was at the end of the year. At the end of December last year, however, the order book decreased by 32% from H1 25. And as you can see from this graph, the decrease already happened during H2 25, when part of the H1 order book was recognized as revenue. It is now important to note the following. You also mentioned that we have different kinds of agreements in the order book. Some orders are short-term, but there are also orders related to multi-year agreements. And in those multi-year agreements, the revenue will be recognized more or less evenly throughout the agreement period and actually on monthly installments in case of right-to-access customers. The revenue decreased by 46% from last year. H1. The decrease was driven by a decrease in clinical revenue. The clinical revenue decreased by 57%. However, it is important now to go back to the previous slide and remember that the order book of €3.5 million included €2.8 million of order book for clinical business. The H1 26 revenue was negatively impacted by delays in some customer cases. And then when we look at the H1 of last year and H1 of this year, like Jukka already indicated, there is a different kind of revenue recognition happening between these two halves of the year. We can see that almost entirely the revenue is annually repeatable, meaning that it either comes from annually recurring license fees or it is based on the usage during the period. On the other hand, when we look at last year. In H1, we had their revenue recognized from multi-year agreements at a single point in time. Today, when we look at the agreements that we have and also agreements that we are negotiating with the customers, we are clearly seeing that the market is evolving more towards right-to-access type of agreements, where the revenue is recognized more evenly over the agreement period. And then lastly, about financing. So, like Jukka already mentioned, we had the equity financing round, but this time we are also happy to discuss other news in the financing space. So we have signed a venture debt loan agreement with the European Investment Bank for up to €20 million. The agreements were signed one month ago at the end of July. The loan agreement includes three different tranches of five, seven, and €8 million, and each of these tranches has its own availability period. The longest availability period is 36 months from signing the agreement. The EIB conducted a thorough due diligence on Aiforia Technologies Plc during the negotiation phase and decided to commit to us. We see that this is a very valuable external validation of the Aiforia Technologies Plc case. The loan financing complements equity financing while it limits immediate dilution, as the related warrants are synthetic and will be settled in cash. The company intends to use the loan financing to accelerate product development, and it also supports commercial expansion. The contract has been signed, but none of the tranches has yet been raised. Each of the tranches is conditional on certain milestones. For example, it is related to revenue. So we can conclude on this that the capital is available as soon as we deliver results to the EIB. And that would be all from my side. Thank you very much. And we can move to Q&A.

Operator
33:08 - 33:11

Okay. Thank you. Any questions?

Unknown 1
33:19 - 33:53

Hey. Maybe starting from the feeling among your clinical customers looking at the market, there seems to be still a clear need for efficiency solutions and changing the way pathology is done. In a certain sense, it just feels that the sense of urgency has not been as high so far. But have you seen any change in that, given that the customers that are taking time to adopt the solutions are feeling the pressure mounting in the background, or how do you see the sentiment changing?

Antti Ojala
33:53 - 36:45

I think the timing is getting better and better on this topic. So, because we have those few customers who are in production in Finland. This is moving forward really nicely. They are actually consuming more than they originally planned. The thing is that once they start using our solution, they are not going to go back. But the challenge is that, as I mentioned before, you need to have all the components in place. You need to organize the workflow. I think some organizations are underestimating all the transformation on the human side required to change organizational habits. But once they start using it, they are not going to go back and they are really happy. That is positive and really comforting news for us. The other one is Paris. They have this prostate tool in production, and they also stated publicly that they are extremely happy with it. So they would never go back to the old habits. We have some other customers as well. And that tells me concretely the market sentiment. We have a big customer in Italy that we delivered to a couple of years ago, but they didn't have the scanners and it took them three years to finalize the scanner purchase. And now they are coming next week. According to yesterday's information. But they are getting it finally. This means that everything is implemented. Once they get the scanners in place, they get the digital slides. Then there is an opportunity to pick up the volume. It has been taking far too long. But okay, it is happening. The positive thing was also that I was visiting US customers a couple of weeks back, and they have very large organizations, and now it is totally different than it was a couple of years ago. They did not have scanners. We visited one that has already purchased 36 scanners for the full new laboratory. They bought an image management system. And now the next step is to finalize the whole project with the AI. You need to have those steps in place, and you always a little bit underestimate the time it will take from one point to another, because already 3 or 4 years ago, it was obvious that this market would be the driver and it would happen. But now it seems that when you get all the components in place, it starts happening and it can start happening quickly. The other thing is obviously that the demand is there. As I mentioned, 40% of the pathologists are over 60 years old. This means that eventually it has to happen because the case volume is there and growing. And the capacity to handle it is going down. So all the drivers are there. But we will see.

Unknown 1
36:45 - 36:45

Yeah.

Antti Ojala
36:45 - 36:46

Yeah.

Unknown 1
36:47 - 37:08

Continuing on what you just said, with some customers investing in scanners before they start talking to us about AI, is it fair to say that in the past, it has been the other way around, where they get excited about AI and then realize the scanner requirements and infrastructure they need to build? And now that they are focusing more on infrastructure first and then coming to you, do you see a shift of that sort in the market?

Antti Ojala
37:09 - 38:17

Yes, okay. We have some customers, and I still believe in that logic. So when we negotiate, we say, okay, once you implement the laboratory information system and image management system, it makes sense to implement all the AI components. And that is what they did. But then they were delayed in actually getting the hardware in. The good thing is that now everything is implemented, but it goes the other way around with some customers, although I do not see a significant shift in that regard. So the scanners are good today. So, you have a multiple choice with the high-quality scanners, and you get the high-quality images. That is not a problem at all. Also, all the software technology components are at a solid level, so you can actually perform the work and start having referenceable customers, which is really important. We have people who are willing to talk about the Aiforia Technologies Plc implementation, how they are using it, and how they are satisfied, which speeds up adoption for the next customers to come. Yeah.

Unknown 1
38:18 - 38:38

Maybe we can move on to discuss our geographic expansion. Europe has obviously been the strong market so far with most customers coming from there. The US market has taken longer to develop. How does that market feel to you right now? Are there more movements happening there? Is the regulatory landscape moving in a good direction? How do you see it?

Antti Ojala
38:38 - 38:39

Meaning the US?

Unknown 1
38:39 - 38:39

US.

Antti Ojala
38:39 - 38:40

Yes.

Unknown 1
38:40 - 38:40

Yeah.

Antti Ojala
38:41 - 40:02

Well, yes. I spent three days. I visited three very large customers. And I think they are all ready to move forward. The regulatory part is not the problem. So they use the LDT laboratory. Laboratory-developed test processes allow them to qualify themselves. So there is no competition. There are a couple of companies that have received FDA approval for something, perhaps a viewer or a similar component. However, that is not the solution. So there is no competition that would have an FDA-approved offering in place. Everybody uses LDTs. And then it is a case that those are different than the European ones. They are a private, non-profit organization. But the decision-making is different compared to European public sector heavy tendering processes and so on. But in the US, they want to test. They want to start a pilot. So they evaluate themselves. And when they are ready to go, they go. But I see that the US is picking up as well. But then for Aiforia Technologies Plc, the question is, where should we focus? We definitely maintain our presence in the US. But the European market is really the one where we have the biggest advantage at the moment.

Unknown 1
40:03 - 40:29

Yeah, yeah. Moving to the sales topic in general, you mentioned that you have a significant list of partners that are collaborating with you on sales. What is your feeling regarding the importance of that channel going forward? You did mention that a few have more weight in your mind regarding that channel, but do you think that channel is going to pick up, or is that something that is a slower, longer tail?

Antti Ojala
40:30 - 42:46

Yeah. So, when we talk about the ecosystem play. We have, of course, these big partnerships. We have partnerships with all the cloud providers. We have partnerships with the scanner and image management vendors on the technology side. And then we have some co-selling where they find an opportunity or we find an opportunity. Both sell their own offerings, and that works nicely. So, in my presentation, I was referring to the reselling partners that actively find opportunities and drive sales cycles. And on that point. We want to take the learnings from the software industry. We are looking at other industries to see how they manage their channels so that we can improve our approach. We need to focus on those who are willing to invest in the topic, and perhaps train people who have access. Access to a customer who has the skills to sell it. And we can provide them support on that activity. We need to categorize them a bit so that we understand where to invest if we decide to pursue certain partnerships. So the partner needs to put something on the table from their side as well. But I honestly believe that the channel is the way to scale up. If you look at the very large software companies, like, for instance, a totally different category. I mentioned SAP. If SAP has their own professional services with 10,000 people, but they also have 40,000 to 50,000 from Accenture and Deloitte, all the big firms have tens of thousands of people working on an SAP practice. And I think that that is the way to scale up that company. However, when you are entering the market. So then you need to build it yourself. You cannot rely solely on our partners. But as we start getting more volume, it will attract more partners and speed up the scaling process. That is something that we need to start investing in now and take to the next level. But we have actually 39 partners globally. As I said, maybe five are truly meaningful as they bring opportunities for us and we work together. However, there are a lot of companies that want to partner with us.

Unknown 1
42:47 - 43:22

Yes, certainly. Then, going back to revenue a little bit, I think you commented on this quite a bit already, regarding how your customers' usage of Aiforia Technologies Plc has been developing. I believe you noted that the diagnostics volumes are increasing very nicely. But just to go there, because the clinical revenue came down quite a bit. Was there any kind of influence of a clinical customer reducing or backtracking their intended use? Or was it simply just the kind of revenue recognition that was playing into it?

Antti Ojala
43:22 - 44:19

Okay. All right. And thanks. Thanks for asking this question. I really wanted to comment on that. I read some comments in different places asking if we have lost customers. We have not lost any customers. And that is why we have this customer success team in place now as well. The target is that the logo churn is zero and the revenue churn is zero, as none of the customers on the clinical side who started using our platform have stopped or decreased their usage. So everything is going up. And in the same way, we haven't lost any logos among those clinical customers. It probably will happen someday, but so far all is good in that sense. Our biggest challenge is getting it into routine use. Once the first applications are in routine use. So then it is easy to expand from that. So, all is well on that front.

Unknown 1
44:20 - 44:21

Okay, thanks from me.

Unknown 2
44:30 - 44:50

We have two questions from the chat. These are actually in Finnish. Let's take this. Maybe you can also answer in Finnish, as I believe we have at least partially answered this in English. Okay. The first question is: Antti Ojala. Diagnostica.

Antti Ojala
44:53 - 45:30

No. Onko joku joka. Tau. Tau I Diagnostica ei korvaa. Jotka. Investor. Pathology R&D. E.

Unknown 2
45:42 - 45:54

E. E Laguna Seca. Aiforia Technologies. Tasks versus goals.

Jukka Tapaninen
46:00 - 46:58

Total. Continuing. Next. NE se. It was. On. Looking. Aiforia. Modern. None. Nyan. Jatkuva. Moving on. Jatkuva. Corta. Core. Also. Revenue growth continues. Revenue ratios. Revenue. U.S. In addition.

Unknown 2
47:02 - 47:15

Thank you. And now we have received one more question in English. Describe your understanding of FDA regulation. Possible changes. Is your company involved in discussions with the FDA regarding timetables?

Antti Ojala
47:18 - 48:46

Well, okay. I can start from that by saying we have regular contact with the FDA. We have been visiting them. We have been discussing this topic regarding how it should be done and how it is evolving within the FDA. There have been a lot of changes within the new administration in the US. But the earlier challenge was that they were talking about the digital pathway, so that once you take an FDA approval for a certain AI model, you need to have the same process or the same kind of approval. You need to have the scanner. You need to have the image management system. You need to have the screen, and you need to have the AI model. The challenge with this approach was that if one of those components, for example the scanner, becomes obsolete, then the entire process becomes obsolete at once. It is a quite significant investment for companies. That is why the companies, not just us, but everybody else are in this position. They are hesitant to invest in that process because it is not a sustainable model. The discussion we have with them is that, can we decouple these components? And if that happens. So then it opens up the path to get an FDA approval for diagnostic AI models as well.

Unknown 2
48:47 - 48:50

Thank you. I believe those were all the questions for today.

Antti Ojala
48:52 - 48:52

Thank you.

Jukka Tapaninen
48:54 - 48:55

Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…